Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HER-2-targeted therapy: lessons learned and future directions.

Rita Nahta1, Francisco J Esteva

  • 1Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 14, 2003
PubMed
Summary

Accurate assessment of HER-2 expression is crucial for breast cancer patients. This review covers current and developing HER-2 targeted therapies to improve treatment outcomes and combat resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refining Stratification in Premenopausal Node-Positive HR<sup>+</sup>/HER2<sup>-</sup> Breast Cancer With a Novel AI-Based Test.

Clinical breast cancer·2026
Same author

Multi-modal AI for comprehensive breast cancer prognostication.

Nature communications·2026
Same author

Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium.

Clinical breast cancer·2025
Same author

Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study.

Lancet regional health. Americas·2024
Same author

Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.

JCO oncology practice·2024
Same author

Next-Generation HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.

Cancers·2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • HER-2 overexpression occurs in 20-25% of invasive breast cancers, correlating with aggressive disease and poorer survival.
  • HER-2 status dictates patient response to trastuzumab, a critical HER-2 targeted antibody.
  • Trastuzumab combined with chemotherapy improves outcomes but resistance develops within a year for most patients.

Purpose of the Study:

  • To review current and investigational HER-2 targeting strategies for breast cancer treatment.
  • To highlight the importance of accurate HER-2 assessment for therapeutic selection.

Main Methods:

  • Literature review of HER-2 targeted therapies in breast cancer.
  • Analysis of treatment efficacy and resistance mechanisms.

Related Experiment Videos

Main Results:

  • HER-2 targeted therapy, particularly trastuzumab, offers significant benefits when HER-2 is overexpressed.
  • Chemotherapy combined with trastuzumab enhances response rates and survival.
  • Acquired resistance to trastuzumab remains a significant clinical challenge.

Conclusions:

  • Accurate HER-2 assessment is vital for guiding breast cancer treatment decisions.
  • Ongoing research into novel HER-2 targeting strategies is essential to overcome resistance and improve long-term patient survival.